Table 1.
Characteristics and clinical course of patients with mild to moderate or severe confirmed COVID‐19
| Characteristics | Patients with mild to moderate or severe COVID‐19 N = 57 |
|---|---|
| Age, median (IQR) | 52 (35–69.5) |
| Male sex, n (%) | 32 (56.1) |
| Body mass index, median (IQR) | 23.8 (21.0–26.5) |
| Pneumonia, n (%) | 37 (64.9) |
| Smoking history (none/past/current) | 33/17/7 |
| History of close contact with individuals with confirmed cases | 16 (28.1) |
| Days from onset of symptoms to admission, median (IQR) | 8 (5–12) |
| Comorbidities | |
| Hypertension, n (%) | 16 (28.1) |
| Cardiovascular diseases, n (%) | 5 (8.8) |
| Chronic obstructive pulmonary disease, n (%) | 4 (7.0) |
| Asthma, n (%) | 8 (14.0) |
| Diabetes mellitus, n (%) | 13 (22.8) |
| Hyperlipidemia, n (%) | 20 (35.1) |
| Chronic kidney disease, n (%) | 5 (8.8) |
| Hemodialysis, n (%) | 3 (5.3) |
| Solid tumor, n (%) | 1 (1.8) |
| Pregnancy, n (%) | 2 (3.5) |
| Use of medication for comorbidities | |
| ARB, n (%) | 8 (14.0) |
| Calcium blocker, n (%) | 9 (15.8) |
| Statin, n (%) | 12 (21.1) |
Abbreviations: ARB, angiotensin receptor blocker; COVID‐19, coronavirus disease‐2019; IQR, interquartile range.